Page last updated: 2024-11-12

2-furoyl-ligrlo-amide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10395438
CHEMBL ID509819
MeSH IDM0468319

Synonyms (11)

Synonym
CHEMBL509819 ,
bdbm50412718
2-furoyl-ligrlo-amide
729589-58-6
AKOS024457384
n-[(2s)-1-[[(2s,3s)-1-[[2-[[(2s)-5-(diaminomethylideneamino)-1-[[(2s)-1-[[(2s)-1,5-diamino-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]furan-
CS-0029361
HY-P1314
2-(2-furoyl)-leu-ile-gly-arg-leu-orn-nh2
MS-31409
PD019049
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteinase-activated receptor 2Homo sapiens (human)IC50 (µMol)0.10000.00251.34796.6000AID772494
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteinase-activated receptor 2Homo sapiens (human)EC50 (µMol)0.25310.02512.288310.0000AID1433198; AID1658705; AID1658707; AID1695460; AID363236; AID772493
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (55)

Processvia Protein(s)Taxonomy
vasodilationProteinase-activated receptor 2Homo sapiens (human)
T cell activation involved in immune responseProteinase-activated receptor 2Homo sapiens (human)
positive regulation of leukocyte chemotaxisProteinase-activated receptor 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseProteinase-activated receptor 2Homo sapiens (human)
positive regulation of glomerular filtrationProteinase-activated receptor 2Homo sapiens (human)
inflammatory responseProteinase-activated receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProteinase-activated receptor 2Homo sapiens (human)
blood coagulationProteinase-activated receptor 2Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
regulation of blood coagulationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of cell migrationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of actin filament depolymerizationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of pseudopodium assemblyProteinase-activated receptor 2Homo sapiens (human)
negative regulation of chemokine productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of chemokine productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of type II interferon productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-10 productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-6 productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of interleukin-8 productionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of superoxide anion generationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of toll-like receptor 2 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
negative regulation of toll-like receptor 3 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of toll-like receptor 3 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of Rho protein signal transductionProteinase-activated receptor 2Homo sapiens (human)
neutrophil activationProteinase-activated receptor 2Homo sapiens (human)
regulation of canonical NF-kappaB signal transductionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of eosinophil degranulationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of GTPase activityProteinase-activated receptor 2Homo sapiens (human)
innate immune responseProteinase-activated receptor 2Homo sapiens (human)
cell-cell junction maintenanceProteinase-activated receptor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIProteinase-activated receptor 2Homo sapiens (human)
regulation of JNK cascadeProteinase-activated receptor 2Homo sapiens (human)
negative regulation of JNK cascadeProteinase-activated receptor 2Homo sapiens (human)
positive regulation of JNK cascadeProteinase-activated receptor 2Homo sapiens (human)
negative regulation of insulin secretionProteinase-activated receptor 2Homo sapiens (human)
leukocyte migrationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of chemotaxisProteinase-activated receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisProteinase-activated receptor 2Homo sapiens (human)
defense response to virusProteinase-activated receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProteinase-activated receptor 2Homo sapiens (human)
positive regulation of phagocytosis, engulfmentProteinase-activated receptor 2Homo sapiens (human)
establishment of endothelial barrierProteinase-activated receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProteinase-activated receptor 2Homo sapiens (human)
thrombin-activated receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
leukocyte proliferationProteinase-activated receptor 2Homo sapiens (human)
positive regulation of neutrophil mediated killing of gram-negative bacteriumProteinase-activated receptor 2Homo sapiens (human)
mature conventional dendritic cell differentiationProteinase-activated receptor 2Homo sapiens (human)
potassium channel activating, G protein-coupled receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
positive regulation of renin secretion into blood streamProteinase-activated receptor 2Homo sapiens (human)
regulation of chemokine (C-X-C motif) ligand 2 productionProteinase-activated receptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProteinase-activated receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingProteinase-activated receptor 2Homo sapiens (human)
protease bindingProteinase-activated receptor 2Homo sapiens (human)
G protein-coupled receptor activityProteinase-activated receptor 2Homo sapiens (human)
signaling receptor bindingProteinase-activated receptor 2Homo sapiens (human)
protein bindingProteinase-activated receptor 2Homo sapiens (human)
thrombin-activated receptor activityProteinase-activated receptor 2Homo sapiens (human)
G-protein beta-subunit bindingProteinase-activated receptor 2Homo sapiens (human)
signaling receptor activityProteinase-activated receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
early endosomeProteinase-activated receptor 2Homo sapiens (human)
Golgi apparatusProteinase-activated receptor 2Homo sapiens (human)
plasma membraneProteinase-activated receptor 2Homo sapiens (human)
pseudopodiumProteinase-activated receptor 2Homo sapiens (human)
plasma membraneProteinase-activated receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1658712Stability in rat plasma assessed as drug degradation after 1 hr by LC-MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of Novel Nonpeptidic PAR2 Ligands.
AID1433202Agonist activity at PAR2 in human MDA-MB-231 cells assessed as induction of chemotaxis at 100 nM incubated for 24 hrs by transwell migration assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Potent Small Agonists of Protease Activated Receptor 2.
AID1433200Agonist activity at PAR2 in human PC3 cells assessed as induction of intracellular calcium release at 25 uM of first compound treatment followed by 100 uM of second compound treatment by Fluo-3 AM dye based fluorescence assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Potent Small Agonists of Protease Activated Receptor 2.
AID1658708Agonist activity at PK1-tagged PAR2 (unknown origin) expressed in HEK293 cells assessed as induction of beta-arrestin recruitment incubated for 90 mins by Pathhunter chemiluminescent assay relative to 2f-LIGRLO-NH22020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of Novel Nonpeptidic PAR2 Ligands.
AID1658707Agonist activity at PK1-tagged PAR2 (unknown origin) expressed in HEK293 cells assessed as induction of beta-arrestin recruitment incubated for 90 mins by Pathhunter chemiluminescent assay2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of Novel Nonpeptidic PAR2 Ligands.
AID363237Agonist activity at human PAR2 expressed in HEK293T cells assessed as effect on intracellular calcium mobilization by R-SAT assay relative to SLIGRL-NH22008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of potent and selective small-molecule PAR-2 agonists.
AID772494Displacement of [3H]-2-furoyl-LIGRL-NH2 from human PAR2 expressed in human NCTC-2544 cells after 60 mins by scintillation counting analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Toward drugs for protease-activated receptor 2 (PAR2).
AID1433209Induction of intracellular calcium release in PAR2 deficient CHO cells at 100 uM measured for 300 secs by Fluo-3 AM dye-based fluorescence assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Potent Small Agonists of Protease Activated Receptor 2.
AID1695460Agonist activity at PAR2 in human EA.hy926 cells assessed as stimulation of calcium mobilization by Fluo-4-AM dye-based FLIPR assay2020RSC medicinal chemistry, Aug-01, Volume: 11, Issue:8
Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2.
AID1658706Agonist activity at human PAR2 expressed in HEK293T cells assessed as induction of Galphaq-stimulated IP1 formation incubated for 2 hrs by FRET assay relative to 2f-LIGRLO-NH22020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of Novel Nonpeptidic PAR2 Ligands.
AID1433203Agonist activity at PAR2 in human MDA-MB-231 cells assessed as induction of chemotaxis at 100 nM incubated for 24 hrs cells preincubated with PAR2 antibody SAM11 prior to test compound addition by transwell migration assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Potent Small Agonists of Protease Activated Receptor 2.
AID1658711Metabolic stability in Sprague-Dawley rat liver microsomes assessed as CYP450-mediated drug degradation at 20 uM measured up to 60 mins in presence of NADPH by LC-MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of Novel Nonpeptidic PAR2 Ligands.
AID363236Agonist activity at human PAR2 expressed in HEK293T cells assessed as effect on intracellular calcium mobilization by R-SAT assay2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of potent and selective small-molecule PAR-2 agonists.
AID772493Agonist activity at PAR2 in human HT-29 cells assessed as increase in intracellular calcium release2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Toward drugs for protease-activated receptor 2 (PAR2).
AID1658705Agonist activity at human PAR2 expressed in HEK293T cells assessed as induction of Galphaq-stimulated IP1 formation incubated for 2 hrs by FRET assay2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of Novel Nonpeptidic PAR2 Ligands.
AID1433198Agonist activity at human PAR2 expressed in CHO cells assessed as induction of intracellular calcium release measured for 300 secs by Fluo-3 AM dye-based fluorescence assay2016ACS medicinal chemistry letters, Jan-14, Volume: 7, Issue:1
Potent Small Agonists of Protease Activated Receptor 2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (25.00)29.6817
2010's40 (71.43)24.3611
2020's2 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.01 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]